DEFA14A: Hologic to Go Private in Blackstone, TPG Acquisition

Hologic, Inc. announced its unanimous board-approved acquisition by Blackstone and TPG, aiming to accelerate growth as a private company.

Summary

• Hologic, Inc. will be acquired by investment firms Blackstone and TPG, transitioning into a private company.
• The Hologic Board of Directors has unanimously approved the merger agreement and recommends that stockholders approve the transaction.
• The acquisition is expected to close in the first half of calendar 2026, subject to stockholder and regulatory approvals.
• Upon completion, Hologic's common stock will be delisted from Nasdaq, but the company will continue to operate under the Hologic name and brand.
• The transaction is presented as an excellent opportunity for stockholders, employees, customers, and patients, promising enhanced resources for growth and innovation, particularly in women's health.

Sentiment

Score: 8

Explanation: The filing presents the acquisition in a highly positive light, emphasizing benefits for all stakeholders, strategic growth, and continuity. While standard risks are disclosed, the overall tone and stated rationale are very optimistic about the future as a private entity.

Positives

• The transaction is viewed as an excellent opportunity for Hologic, its stockholders, employees, customers, and patients.
• Hologic is well-positioned for success as a private company due to its stable businesses, strong profitability, cash flows, and balance sheet.
• Partnership with Blackstone and TPG is expected to enhance Hologic's global positioning, reduce capital constraints, and expand resources for investment in growth and innovation.
• The acquisition is anticipated to accelerate growth and strengthen Hologic's leadership in women's health globally.
• The transaction is expected to deliver immediate and compelling value to Hologic stockholders.
• Blackstone and TPG are committed to supporting Hologic's unique company culture, purpose, passion, and promise.
• For the vast majority of employees, the change is expected to be seamless, with day-to-day jobs remaining largely the same and a long-term positive outlook.
• Continuity in production, sales of existing products, and excellent customer relationships are key near-term priorities for the new owners.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or cause the abandonment of the proposed transaction.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• There is a possibility that Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The proposed transaction could disrupt management time from ongoing business operations.
• Announcements related to the proposed transaction could adversely affect the market price of Hologic's common stock.
• There is a risk of unexpected costs or expenses resulting from the proposed transaction.
• The proposed transaction could lead to litigation.
• The transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel, maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships, and impact its operating results and business generally.
• Holders of Contingent Value Rights (CVRs) may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

Hologic expects to be better positioned globally as a private company, leveraging enhanced flexibility and resources from Blackstone and TPG to accelerate growth and strengthen its leadership in women's health. The transaction is anticipated to close in the first half of 2026.

Management Comments

• "We believe this is an excellent opportunity for Hologic as a whole, and more specifically for our stockholders, employees, customers and patients."
• "Hologic is well positioned for success as a private company, given our large businesses in stable, established sectors, and our strong profitability, cash flows and balance sheet."
• "With Blackstone and TPG, Hologic will be even better positioned globally, with fewer capital constraints and expanded resources to invest in growth and innovation."
• "Blackstone and TPG will enhance our ability to deliver critical medical technologies that benefit customers and patients."
• "The transaction delivers immediate and compelling value to Hologic stockholders."
• "We firmly believe their cultures and approaches are squarely aligned with ours—they are each excited about the chance to partner with us and work with our highly talented teams."
• "Blackstone and TPG are fully committed to supporting our Purpose, Passion and Promise. They believe our Company, our people and our products play an indispensable role in advancing womens health."
• "For the vast majority of employees, we expect this change to be seamless, for day-to-day jobs to remain largely the same, and for this to be a long-term positive."

Industry Context

The acquisition of Hologic, a medical technology company focused on women's health, by private equity firms Blackstone and TPG, aligns with a broader industry trend where private capital seeks stable, profitable businesses with significant growth potential in specialized healthcare sectors. This strategy often allows companies to pursue long-term strategic objectives, such as increased investment in research and development or market expansion, away from the short-term pressures of public market reporting.

Corporate Governance

Legal Proceedings

• The filing mentions the risk of any litigation relating to the proposed transaction, but no current legal proceedings are detailed.

Stakeholder Impact

• Shareholders: Will receive immediate and compelling value from the acquisition; will no longer hold Hologic common stock after delisting; need to approve the transaction.
• Employees: Expected seamless transition, day-to-day jobs largely the same, long-term positive outlook; company culture supported; subject to trading policy restrictions.
• Customers: Enhanced ability to deliver critical medical technologies; continuity in production and sales; excellent customer relationships maintained.
• Patients: Benefits from critical medical technologies; advancement of women's health.
• Vendors/Partners: Relationships maintained.

Next Steps

• Hologic will file a proxy statement with the SEC, which will include a detailed history of the transaction.
• Hologic stockholders need to approve the transaction and adopt the merger agreement.
• Various required regulatory approvals must be received.
• The transaction is expected to close in the first half of calendar 2026.
• Upon completion of the transaction, Hologic's common stock will be delisted from Nasdaq.

Key Dates

Recommendation

The company is undergoing an acquisition that has been unanimously approved by its board, with a recommendation for stockholder approval. The transaction is expected to close in the first half of 2026. For existing shareholders, holding the stock until the acquisition closes is the logical strategy to realize the value offered by the acquirers, assuming the deal terms are favorable and the transaction is likely to be completed.

Keywords

Hologic, Blackstone, TPG, acquisition, merger, private equity, women's health, medical technology, delisting, corporate governance